|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 27 April 2022, 9:05. The announcement is not marked as price sensitive, and is 54 page(s) in length and 1.72MB in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.004% short sold according to ASIC data. It was ranked the 657th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Annual Report to shareholders | 27 April 2022, 9:05 |
| FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial | 25 March 2022, 9:54 |
| FDA approval for Phelan-McDermid IND and Phase 2 trial | 23 March 2022, 9:44 |
| Ethics approval for Angelman Phase 2 trial in Australia | 11 March 2022, 9:33 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 